Gsk (GSK) Income from Discontinued Operations (2021 - 2022)
Gsk (GSK) posted quarterly Income from Discontinued Operations of 513742604.66 for Q4 2022, down 64.35% year-over-year from 1441023339.08 in Q4 2021, and down 95.67% quarter-over-quarter from 11858552941.72 in Q3 2022.
Gsk (GSK) Income from Discontinued Operations (2021 - 2022) Analysis & Trends
Gsk's Income from Discontinued Operations history runs 2 years deep, the most recent figure standing at 513742604.66 for Q4 2022.
- In Q4 2022, Income from Discontinued Operations fell 64.35% year-over-year to 513742604.66; the TTM figure through Dec 2022 stood at 12949126746.2 (up 423.62% YoY), while the FY2022 annual figure was 12988707629.47, up 783.1% from the prior year.
- Income from Discontinued Operations for Q4 2022 stood at 513742604.66, down from 11858552941.72 in the prior quarter.
- The five-year high for Income from Discontinued Operations was 11858552941.72 in Q3 2022, with the low at 166229474.91 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 8.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 513.74 Mn |
| Sep 30, 2022 | 11.86 Bn |
| Jun 30, 2022 | 166.23 Mn |
| Mar 31, 2022 | 410.60 Mn |
| Dec 31, 2021 | 1.44 Bn |
| Sep 30, 2021 | 401.17 Mn |
| Jun 30, 2021 | 252.99 Mn |
| Mar 31, 2021 | 377.82 Mn |